FILE PHOTO: Michelle Chester, DNP, director, employee health services, Northwell shows the Moderna coronavirus disease (COVID-19) vaccine at Northwell Health's Long Island Jewish Valley Stream hospital in New York, U.S., December 21, 2020. REUTERS/Eduardo Munoz
ZURICH (Reuters) - As 2020 closes, regulatory approval of COVID-19 vaccines has raised hopes the world can defeat the pandemic next year. But production and delivery challenges suggest beating the disease will be a marathon whose finish line is still far away.
Europe on Monday followed Britain and the United States in giving a green light to a COVID-19 vaccine from Pfizer and its partner BioNTech which, like a similar shot from Moderna that has U.S. emergency approval, demonstrated 95% efficacy in large trials.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
